An Expanded Access Program of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Cretostimogene grenadenorepvec (Primary)
- Indications Bladder cancer
- Focus Expanded access; Therapeutic Use
- Sponsors CG Oncolgy
Most Recent Events
- 20 Nov 2024 According to a CG Oncolgy media release, company announced trials in Progress Posters highlighting on cretostimogene, will be presented at the Society of Urologic Oncology (SUO) 25th Annual Meeting taking place at the Sheraton Dallas Hotel in Dallas, TX, from December 4 - 6, 2024.
- 11 Jun 2024 New trial record